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Abstract
Background: Thymidylate synthase (TS) is an important target for chemotherapeutic treatment
of cancer and high expression of TS has been associated with poor prognosis or refractory disease
in several cancers including colorectal and head and neck cancer. Although TS is known to regulate
cell cycles and transcription factors, its potency as a therapeutic target has not been fully explored
in adenoid cystic carcinoma (ACC).
Methods: An ACC cell line (ACC3) was transfected with siRNA targeting the TS gene and
inhibition of cell growth and induction of apoptosis-associated molecules were evaluated in vitro. In
addition, the in vivo effect of TS siRNA on tumor progression was assessed using a xenograft model.
Results: Our results demonstrated that ACC3 cells showed significantly higher TS expression than
non-cancer cell lines and the induction of TS siRNA led to inhibition of cell proliferation. The effect
was associated with an increase in p53, p21, and active caspase-3 and S-phase accumulation. We
also found up-regulation of spermidine/spermine N1-acetyltransferase (SSAT), a polyamine
metabolic enzyme. Furthermore, treatment with TS siRNA delivered by atelocollagen showed a
significant cytostatic effect through the induction of apoptosis in a xenograft model.
Conclusion: TS may be an important therapeutic target and siRNA targeting TS may be of
potential therapeutic value in ACC.
Background
Adenoid cystic carcinoma (ACC) is one of the most com-
mon salivary gland carcinomas and has indolent charac-
teristics and an ultimately fatal outcome. Although ACC is
thought to typically grow slowly, late occurrence of loco-
regional recurrence and distance metastasis is very com-
mon because of a propensity for perineural invasion. ACC
shows various histological patterns including tubular, cri-
briform, and solid types. It has been widely accepted that
the prognosis for tumors that predominantly comprise
Published: 26 November 2008
BMC Cancer 2008, 8:348 doi:10.1186/1471-2407-8-348
Received: 16 May 2008
Accepted: 26 November 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/348
© 2008 Shirasaki et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:348 http://www.biomedcentral.com/1471-2407/8/348
Page 2 of 12
(page number not for citation purposes)
solid patterns is worse than that of those with a tubular or
cribriform pattern [1]. Several molecules, including p16,
p27, and E-cadherin, have been proposed as prognostic
markers [2-4], but markers useful as therapeutic targets
have not been identified in ACC.
Thymidylate synthase (TS), a folate-dependent enzyme,
plays a crucial role in DNA biosynthesis. TS catalyzes the
transfer of one methyl group from methylenetetrahydro-
folate to generate deoxythymidine-5'-monophosphate
(dTMP) from 2'-deoxyuridine-5'-monophosphate
(dUMP). dTMP is then phosphorylated to 2'-deoxyurid-
ine-5'-triphosphate (dTTP), which is a direct precursor for
DNA. TS is a critical cellular target for 5-fluorouracil (5-
FU), which is widely used in the treatment of several can-
cers including colorectal, breast, and head and neck can-
cer. The cytotoxicity of TS inhibitors, including 5-FU, has
been attributed to the misincorporation of fluoronucle-
otides into DNA and RNA and the inhibition of DNA syn-
thesis induced by the inhibition of TS enzyme activity.
Consequently, the inhibition of TS activity has been
shown to lead to apoptotic cell death resulting from intra-
cellular thymidine depletion [5].
The role of TS as a target for its inhibitors and an oncogene
is controversial and occasionally paradoxical. Overexpres-
sion of the TS gene has been associated with poor progno-
sis or disease refractory to 5-FU-based chemotherapy in
head and neck squamous-cell carcinoma [6]. Although 5-
FU exerts anti-proliferative effects by inhibiting TS expres-
sion, treatment with TS inhibitor has been shown to fre-
quently induce up-regulation of TS expression in cell lines
and tissues from patients treated with 5-FU [7,8]. In addi-
tion, TS overexpression or amplification induced by 5-FU
exposure is associated with the acquisition of resistance to
TS inhibitors [9-12]. Several recent studies have shown
that TS gene induction leads to the acquisition of a malig-
nant phenotype in vitro: transgenic mice overexpressing
human TS in pancreatic islet cells developed islet hyper-
plasia or islet cell tumor [13,14]. On the other hand, we
recently reported that simvastatin, one of the 3-hydroxy-
3-methylglutaryl CoA (HMG-CoA) reductase inhibitors,
exerted anticancer effects with down-regulation of TS
expression [15]. These observations suggest that TS acts as
a putative oncogene as well as a critical target for conven-
tional and novel chemotherapeutic treatments.
There is some experimental evidence that the TS gene
directly or indirectly affects cell proliferation and cell cycle
regulators including the p53 pathway. E2F transcription
factor, a cell cycle accelerator at G1/S phase, has been
shown to induce expression of TS, proliferating cell
nuclear antigen, and cyclin families in quiescent human
cells and overexpression of TS results in down-regulation
of tumor suppressor genes such as p53 and p21 in cancer
cells [16-18]. Cancer cells transfected with mutant p53
have been shown to be more resistant to 5-FU treatment
than parent cells with wild-type p53 [19]. Previous inves-
tigations have revealed that reductive expression of TS by
antisense or small interfering RNA (siRNA) results in inhi-
bition of cell proliferation or improvement in chemosen-
sitivity [20-23]. However, the precise molecular and
biological mechanisms of TS-specific inhibition or silence
have not been fully elucidated. Although a recent investi-
gation showed an intimate relationship between TS over-
expression and poor clinical outcome in ACC, the
significance of TS as a therapeutic target has been yet to be
evaluated in ACC.
In recent years, RNA interference technology using siRNA
has rapidly become a highly specific and powerful tool to
silence target genes. To date, a number of studies have
demonstrated that siRNA can be a novel tool for clarifying
gene function in mammalian cells and may be applicable
to gene-specific therapeutics. There have been no investi-
gations into the efficacy of specific siRNA for the TS gene
in the field of salivary gland cancer. Here, we have evalu-
ated whether silence of the TS gene affects cell prolifera-
tion, cell cycle, and apoptosis in the ACC3 cell line.
Materials and methods
Cell culture
ACC3 cells were grown in DMEM supplemented with
10% fetal bovine serum, L-glutamine, penicillin, and
streptomycin, and maintained at 37°C in a humidified
atmosphere with 95% air and 5% CO2.
Reagents and antibodies
Antibodies for immunoblotting were obtained from the
following sources: mouse monoclonal anti-p21 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA); mouse mon-
oclonal anti-p53 (Calbiochem, Darmstadt, Germany);
rabbit polyclonal anti-active-caspase-3 (BioVision, Moun-
tain View, CA, USA); mouse monoclonal anti-TS(Abcam,
Cambridge, MA, USA); and mouse monoclonal anti-β-
actin (Abcam).
siRNA transfection
The targeted base sequence for human TS was 5'-GGAT-
TCTTCGAAAAGTTGA-3' (Ambion, Austin, TX, USA). As a
negative control, Silencer Negative Control #1 siRNA, a
commercially available siRNA referred to as a nonspecific
control (Ambion), was used. After incubation at 37°C for
24 h, cells were transfected with 50 nmol/L annealed
siRNA oligos using siPORT™ lipid transfection agent
(Ambion) following the manufacturer's protocol. Cells
were treated with transfection agent/siRNA complex for
48 h and subjected to further analyses. For extraction of
RNA and protein and flow cytometry analysis, cells wereBMC Cancer 2008, 8:348 http://www.biomedcentral.com/1471-2407/8/348
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primarily plated at a density of 1 × 105 cells per well in 6-
well plates.
Cell viability assay
The effect of siRNA on cell numbers was determined by
counting viable cells with a Cell Counting Kit-8 (Dojindo,
Kumamoto, Japan). An equal number of cells (5000 cells/
well) in 100 μL of culture medium were seeded into each
well of a 96-well microplate and incubated for 24 h. Then,
the cells were treated with TS siRNA or negative control
siRNA. After incubation for 48 h, 10 μL of Cell Counting
Kit-8 solution was added to each well and the plates were
further incubated for 4 h at 37°C. Spectrophotometric
absorbance was measured at 450 nm, with absorbance at
590 nm for reference.
Cell cycle analysis
After treatment, cells were washed three times with phos-
phate-buffered saline (PBS), and collected by treatment
with EDTA/trypsin solution. Collected cells were then
fixed with 70% cold ethanol, incubated with RNase A (2
mg/mL in PBS), and stained with 50 μg/mL of propidium
iodide (Sigma). Cell cycle data were acquired by FACScan
equipped with Cell Quest software (Becton Dickinson,
San Jose, CA, USA).
Reverse transcription-PCR analysis
Total RNA from cultured cells was extracted using TRIzol
(Invitrogen, Carlsbad, CA, USA) and 1 μg of total RNA
was applied to one-step RT-PCR using a Gene Amp Gold
RNA PCR reagent kit (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer's protocol. Oli-
gomer primers were synthesized for TS (sense 5'-TCT-
GGAAGGGTGTTTTGGAG-3' and antisense 5'-
CCTCCACTGGAAGCCATAAA-3') and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (sense 5'-CGA-
GATCCCTCCAAAATCAA-3' and antisense 5'-GTCTTCT-
GGGTGGCAGTGAT-3') (Sigma Genosys, Hokkaido,
Japan). One-step cDNA synthesis and PCR amplification
were performed at 25°C for 10 min; 42°C for 12 min;
95°C for 12 min; 35 cycles at 94°C for 20 s, each anneal-
ing temperature for 30 s, and 72°C for 30 s; and at 72°C
for 7 min as a final extension. Annealing temperatures to
amplify TS and GAPDH genes were 57°C and 60°C,
respectively. PCR products were electrophoresed on 2%
agarose gels and visualized by ultraviolet illumination.
Real-time quantitative reverse-transcription PCR
For each sample, 1 μg of total RNA was retrotranscribed
with the SuperScript first-strand synthesis system (Invitro-
gen, Carlsbad, CA, USA) in a 20 μL reaction. The obtained
cDNA (10 μL) was then used for each duplicate in real-
time quantitative reverse transcription-PCR, which was
done on an ABI Prism 7700 Sequencing Detection System
(Applied Biosystems, Foster City, CA, USA) using TaqMan
Universal PCR Master Mix (Applied Biosystems) follow-
ing the manufacturer's directions. RNA samples from
human keratinocytes and human adult bronchial epithe-
lial cells (Cell Applications, San Diego, CA, USA) were
applied to real-time RT-PCR as control samples from non-
cancer cells. PCR conditions were 50°C for 2 min and
95°C for 10 min followed by 40 cycles of 95°C for 15 s,
and 60°C for 1 min. TaqMan probes for TS, GAPDH, and
spermidine/spermine N1-acetyltransferase (SSAT) were
from the Assays-on-Demand Gene Expression Assay Mix
(Applied Biosystems). Assay ID numbers for TS, GAPDH,
and SSAT were Hs00426591_m1, Hs99999905_m1 and
Hs00161511_m1, respectively. The expressions of TS and
SSAT genes were standardized using GAPDH as a refer-
ence gene, and relative expression levels for the panel of
cell lines were quantified by calculating 2-ΔΔC
T, where ΔCT
is the difference in CT between target and reference genes.
Western blot analysis
Cells were washed with PBS, and then incubated with
medium containing agents or DMSO alone for control.
After washing with PBS, the cells were then scraped with
lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, and 1 μg/mL leupeptin. After centrifugation, the
supernatant was harvested as a total protein extract and
stored at -80°C. Protein concentrations were measured
using a protein assay reagent (Bio-Rad, Hercules, CA,
USA). Equal amounts of protein (10 μg) were separated
by gradient SDS-PAGE gels (Atto, Tokyo, Japan) and elec-
trophoretically transferred to PDVF membrane (Atto).
The membrane was blocked with 5% skim milk in PBS-
0.1% Tween 20 at room temperature for 1 h. The mem-
brane was incubated with primary antibody at room tem-
perature for 1 h. Immunoreactivity was detected by
sequential incubation with horseradish peroxidase-conju-
gated secondary antibody (Santa Cruz). Peroxidase activ-
ity was visualized by the enhanced chemiluminescence
detection system (Amersham Biosciences, Buckingham-
shire, UK).
Xenograft models in nude mice
A total of 3 × 106 ACC3 cells were suspended in 100 μL
PBS and injected subcutaneously into the right flank of 4-
week-old female BALB/c nu/nu mice (Clea Japan, Tokyo,
Japan). After 10 days, when the tumors had reached an
average volume of approximately 100 mm3, mice were
treated with TS siRNA or Silencer Negative Control #1
siRNA. For the in vivo transfection of siRNA, AteloGene™
(Koken Co., Tokyo, Japan) was used. siRNA-atelocollagen
mixture was prepared according to the manufacturer's
directions. 5 μM of siRNA mixed with 200 μM atelocolla-
gen was injected into tumors. Tumor diameters were
measured at regular intervals with a caliper, and the tumorBMC Cancer 2008, 8:348 http://www.biomedcentral.com/1471-2407/8/348
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volume in mm3 was calculated by the formula: volume =
length × width2 × 0.5. All animals were treated in a
humane manner and managed according to the guide-
lines of our animal facility. To detect apoptotic cells, a
standard terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) assay was performed on
formalin-fixed paraffin-embedded tissues according to
the manufacturer's recommendations (S7101; Chemicon
International, Inc., CA, USA). The number of positive cells
in 1000 tumor cells within 4–6 microscopic fields at × 200
magnification was counted.
Statistical analysis
Statistical analyses were performed by unpaired Student's
t test using SigmaStat statistical software (version 3.1; Sys-
tat Software, Point Richmond, CA). All of the tests were
two-sided. P < 0.05 was considered to be significant. Each
experiment was repeated at least three times.
Results
Overexpression of TS mRNA in ACC3 cells
Initially, the expression level of TS mRNA transcript was
evaluated with real-time RT-PCR using RNA samples from
control non-cancer cell lines derived from skin keratinoc-
ytes and bronchial epithelial cells. Expression in ACC3
cells was significantly higher than in the non-cancer cell
lines. TS gene expression was 11-fold higher in ACC3 cells
than keratinocytes (Fig. 1). When compared with human
adult bronchial epithelial cells, the TS gene expression
was increased 79-fold in ACC3 cells.
Evaluation of TS mRNA transcript expression in the ACC3 cell line Figure 1
Evaluation of TS mRNA transcript expression in the ACC3 cell line. Expression was compared with that in keratino-
cytes and bronchial epithelial cells as normal cell controls using real-time RT-PCR.
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Effect on cell survival of transfection with siRNA targeting 
TS
Next, we examined the effect of TS siRNA transfection on
the viability of ACC3 cells. Transfection of cells with TS
siRNA resulted in dramatically decreased TS expression
(Fig. 2A). Real-time RT-PCR confirmed that the induction
of TS siRNA decreased TS expression to 12% of the level in
cells transfected with negative control siRNA (Fig. 2B).
Western blot comfirmed effect of TS siRNA on protein
expression (Fig. 2C) TS siRNA transfectant cells showed
significantly reduced cell viability in comparison with
control cells. Cell viability was inhibited by 67% in ACC3
(Fig. 2D).
S-phase accumulation of cells by TS silence
We examined whether TS inhibition caused by siRNA
transfection affected the cell cycle. Cell cycle phases were
determined by flow cytometry with propidium iodide
staining. S-phase populations significantly increased,
from 29% to 49%, in ACC3 cells after treatment with TS
siRNA (Fig. 3). Experiments were repeated several times
and identical results were obtained. These results indicate
that TS siRNA leads to cell-cycle arrest at S-phase with a
significant increase in the S-phase population.
Effect of siRNA on the expressions of p53, p21, active 
caspase-3, and spermidine/spermine N1-acetyltransferase 
(SSAT)
To assess the effect of TS suppression on the expressions
of cell cycle- or apoptosis-associated molecules, we
focused on the expression of molecules involved in p53
pathway and apoptosis. Western blot analysis revealed
that cells transfected with TS siRNA showed up-regulation
of p21 and active caspase-3 proteins (Fig. 4A). The anti-
body for p53 detects wild-type p53 protein. Real-time
quantitative RT-PCR analysis demonstrated that the
expression of SSAT mRNA transcript increased 1.8-fold in
TS siRNA-transfected ACC3 cells (Fig. 4B).
Inhibition of tumor growth by TS siRNA in ACC3 tumor 
xenografts
To investigate the antitumor effect of TS siRNA in vivo, we
transfected TS siRNA and negative control siRNA into
BALB/c nu/nu mice bearing ACC3 tumor xenografts. Sub-
cutaneous tumors were developed by injecting 3 × 106
ACC3 cells into the right flank of female nude mice. When
the tumor reached 100 mm3 in volume, TS siRNA or neg-
ative control siRNA was injected and mice were observed
for 2 weeks. The mean tumor volumes on day 14 were
1162 mm3 in the TS siRNA-treated group and 3419 mm3
in the negative control group. Significant differences
between the two groups were found on days 7 and 14 (p
< 0.01) (Fig. 5A and 5B). To assess the involvement of
apoptosis in the suppression of tumor growth after TS
silence, we conducted TUNEL assay and found signifi-
cantly higher proportion of TUNEL-positive cells in TS
siRNA-treated ACC3 cells (Fig. 6C and 6D).
Discussion
Salivary gland carcinomas are uncommon neoplasms,
accounting for approximately 5% of those arising in the
head and neck region [24]. In general, these may be cate-
gorized into low grade and high grade malignancies based
on their origin from either the terminal (intercalated) or
the excretory ductal epithelium, respectively [25]. Biolog-
ical and clinical classifications have been dependent on
the histogenetic classification, but are occasionally diverse
even within those categories [1]. Patients with higher his-
tological grades appear to be more susceptible to locore-
gional recurrence and distant metastasis. However,
effective treatment for unresectable tumors has not been
established [26]. ACC is a representative salivary gland
neoplasm originated from terminal (intercalated) epithe-
lial cells and is characterized by indolent clinical course.
However, most patients eventually succumbed to late-
onset recurrence and distant metastasis. No effective ther-
apeutic targets have been established because of its rarity.
We have shown that siRNA to down-regulate TS expres-
sion effectively inhibited cell proliferation and caused S-
phase arrest in ACC3 cells derived from salivary gland car-
cinoma. We also confirmed that another TS siRNA target-
ing 5'-GGTGACTTTATACACACTT-3' decreased TS mRNA
expression and cell viability to 23% and 78% of the level
in ACC3 cells transfected with negative control siRNA,
respectively (data not shown). Gene knock-down by
siRNA is a highly effective approach to silence gene
expression in experimental as well as therapeutic setting.
However, the interpretation of data is occasionally com-
plicated because of non-specific gene silence, so-called
off-target effects, which results from unintended interac-
tions between silence molecule and cellular components
and inappropriate concentration of siRNA [27]. Our TS-
siRNA effectively suppressed both mRNA and protein. In
cDNA microarray analysis in a squamous cell carcinoma
cell line, our TS-siRNA primarily silenced TS mRNA
expression (manuscript in preparation).
Previous reports have shown that 5-FU treatment leads to
S-phase accumulation in colorectal cancer cells in vitro
and in vivo [28]. In addition, antisense oligodeoxynucle-
otides to down-regulate TS have been shown to induce S-
phase arrest in a murine colon carcinoma cell line and
human cancer cell lines [22,23]. Our data demonstrate
that TS silence predominantly targets the S-phase transi-
tion; thus, TS has a critical role in the regulation of the S-
phase checkpoint. S-phase arrest by TS inhibition may be
regulated by various mechanisms. The present cell cycle
analysis showed that transient silence of TS gene induced
S-phase accumulation without increase in sub-G1 popula-BMC Cancer 2008, 8:348 http://www.biomedcentral.com/1471-2407/8/348
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TS expression suppressed by TS-specific siRNA in ACC3 cells Figure 2
TS expression suppressed by TS-specific siRNA in ACC3 cells. After transfection for 48 h, TS expression was meas-
ured by conventional RT-PCR (A), real-time quantitative RT-PCR (B) and Western blot (C). Effect of TS suppression on cell 
survival in ACC3 cells (D). Cell survival conditions were evaluated by Cell Counting Kit-8 after transfection for 48 h. TS-sup-
pressed cells were less proliferative than control cells (p < 0.01). The results are expressed as mean ± SD. *, P < 0.01, signifi-
cantly different from control.
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Effect of TS suppression on cell cycle in ACC3 cells Figure 3
Effect of TS suppression on cell cycle in ACC3 cells. Representative flow cytometry graphs of cells 48 h after transfec-
tion with TS siRNA or negative control siRNA.
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Effect of TS silence on expression of p53, p21, active caspase-3, and SSAT Figure 4
Effect of TS silence on expression of p53, p21, active caspase-3, and SSAT. Cells were transfected with each siRNA 
for 48 h and then protein and mRNA transcript expression was analyzed by Western blot (A) and real-time quantitative RT-
PCR (B). The results are expressed as mean ± SD. *, P < 0.01, significantly different from control.
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An in vivo study of TS siRNA in ACC3 tumor xenografts Figure 5
An in vivo study of TS siRNA in ACC3 tumor xenografts. 3 × 106 ACC3 cells were injected subcutaneously into the 
right flank of mice. When the tumors reached a volume of approximately 100 mm3, TS siRNA and negative control siRNA 
were injected to the tumors. TS and control siRNA were mixed with atelocollagen. Mice were sacrificed 2 weeks after siRNA 
injection. (A) Three representative xenograft tumors from each group are shown. (B) Tumor size was measured and tumor 
volumes calculated.  Each group consisted of six mice. The values are represented as mean ± SD. *, P < 0.01, significantly differ-
ent from control.
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An in vivo study of TS siRNA in ACC3 tumor xenografts Figure 6
An in vivo study of TS siRNA in ACC3 tumor xenografts. 3 × 106 ACC3 cells were injected subcutaneously into the 
right flank of mice. When the tumors reached a volume of approximately 100 mm3, TS siRNA and negative control siRNA 
were injected to the tumors. TS and control siRNA were mixed with atelocollagen. Mice were sacrificed 2 weeks after siRNA 
injection. (C) After treatment with each siRNA, the xenografts were collected, fixed with 10% formalin, sectioned and stained 
for apoptotic cells by TUNEL method. The brown stain represented the DNA fragmentation of apoptotic cells and the blue 
stain showed the nuclei stain with hematoxylin (original magnification ×400). (D) The cumulative results showed the average 
number of apoptotic cells. Each group consisted of six mice. The values are represented as mean ± SD. *, P < 0.01, significantly 
different from control.
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tion in ACC3 cells. The mechanism of S-phase accumula-
tion induced by TS inhibition has not been fully
understood. However, S-phase arrest seemed to be a com-
mon phenomenon of TS inhibition. TS inhibitors, such as
5-FU and ZD9331, induced increase in sub-G1 popula-
tion or apoptosis after S-phase accumulation [8,29]. Since
the present TS siRNA induction into ACC3 cells is tempo-
ral or transient, S-phase accumulation with activation of
p53 pathway may be considered to be an early event in
pro-apoptotic effect of TS inhibition.
We presently focused on the interaction between TS
silence and apoptotic mechanism. Previous studies have
shown that overexpression of TS gene leads to down-reg-
ulation of p53 or p21 and the treatment with TS inhibitors
leads to induction of p21 [29]. We have demonstrated
here that targeted suppression of TS expression increased
expression of p21 and active caspase-3 along with up-reg-
ulation of wild-type p53 in ACC3 cells. Our present results
appeared to be consistent with previous studies showing
that TS inhibition is associated with S-phase accumula-
tion and p21 activation [22,23,28]. Our data that TS
silence led to p21 up-regulation seemed to be controver-
sial, because p21 activation correlated with G1 arrest in
cell cycle. This discrepancy implies that different cell cycle
mediators play a certain role to control the interaction
between p21 and S-phase arrest induced in TS inhibition.
Here, real-time RT-PCR analysis demonstrated TS mRNA
transcript to be significantly up-regulated in ACC3 cells
compared with non-cancer cell lines. Numerous investiga-
tions have focused on the relationship between TS expres-
sion and resistant activity to TS inhibitory agents.
Comparative genomic hybridization analyses have
revealed that chemoresistance to 5-FU or poor clinical
outcome is associated with gain of the 18p11.32 region
encoding the TS gene [9]. Immunohistochemical study
also showed that overexpression of TS protein was com-
monly observed and associated with resistance to chemo-
therapy in head and neck squamous cell carcinoma [6]. In
the meantime, we found significant amplification of TS
mRNA transcript in ACC3 cells, which were derived from
adenoid cystic carcinoma of the parotid gland. This cell
line has been widely used in a number of studies as a char-
acteristic research model of ACC [30]. Chikamatsu et al.
[31] recently reported that high expression of TS protein
was observed in approximately one third of ACC cases
and was possibly associated with poor clinical outcome.
We have demonstrated here that TS siRNA effectively
inhibited tumor growth through the activation of apopto-
sis in an in vivo xenograft model. Although the efficacy of
conventional chemotherapeutic agents on salivary gland
cancer has been regarded to be limited, TS may be an
important target for the treatment of ACC.
We demonstrated that TS silence by specific siRNA
induced the overexpression of spermidine/spermine N1-
acetyltransferase (SSAT) in ACC3 cells. SSAT is a gene
involved in polyamine metabolism. Polyamines
(putrescine, spermidine, and spermine), derived from
ornithine in the urea cycle, play important roles in cell
growth and cell differentiation by modulating DNA struc-
ture, DNA replication, and DNA repair. SSAT is a major
enzyme in the polyamine degradation pathway [32]. We
focused on the relationship between TS silence and SSAT
expression because there have been several reports that
polyamine metabolism is involved in cellular reaction
induced by chemotherapeutic cytotoxic agents, such as TS
inhibitors. It has been reported that treatment with chem-
otherapeutic agents such as 5-FU and cisplatin induces
up-regulation of SSAT expression in several cancer cell
lines and N1, N11-diethylnorspermine, a polyamine ana-
log, enhances cytotoxic effect of 5-FU and oxaliplatin
along with up-regulated SSAT expression [33-35]. In addi-
tion, overexpression of SSAT has been shown to induce
cell death or apoptosis. Increased expression of SSAT
yields depletion of cellular polyamine content and conse-
quently inhibits cell survival [36]. The detailed mecha-
nisms and involvements of these molecules in TS silence
mechanism are under further investigation.
In summary, our study showed that siRNA targeting TS
efficiently reduced TS expression with inhibited cell
growth in ACC3 cells from salivary adenoid cystic carci-
noma. The cytostatic activity of TS silence appeared to be
associated with cell cycle arrest at S-phase and activation
of p53 pathway. Furthermore, we showed that TS siRNA
delivered by atelocollagen exerted an anti-proliferative
and apoptotic effect in a xenograft model. Further elucida-
tion of the role of TS as an oncogene or therapeutic target
may contribute to the development of optimal treatments
for salivary gland carcinomas including ACC.
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